Fri, Dec 26, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

New investors groups turn to European opportunities but need clarification on regulations

Friday, July 18, 2014

amb
Olivier Kintgen
Benedicte Gravrand, Opalesque Geneva:

New investor groups like U.S. based pension funds and others have started to discover European opportunities offered by European managers, in sectors as diverse as European equities; European corporate credit and loans; new fields like financial credit or the management of liquidity buffers (HQLA); smart Beta 2.0; securitization; European distressed; and investments with longer durations like real estate, infrastructure and infrastructure deb, according to the participants of the recent Opalesque France Roundtable.

However, the advent of new European regulations such as the AIFMD might create a "U.S. retro effect" as some U.S. investors may very well decide to remove their investments from European managers.

As the cost of running AIFMD compliant funds will increase, Denis Beaudoin comments, "these investors don’t see any reason why they should pay for those changes and cost increases when they were not requesting them in the first place." Beaudoin is the Founder and current CEO of Finaltis, which provides investment solutions, asset management ($300m) of a CTA and a European market neutral equity strategy, and operational help to new managers.

"As a result of that we have to carefully craft a new way to attract U.S. investors," he continues, "because (they) still are the major pool of demand for us and ou......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its